

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97790 A2

(51) International Patent Classification⁷: **A61K 31/00**

(21) International Application Number: PCT/EP01/07064

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0015447.6 23 June 2000 (23.06.2000) GB

(71) Applicant (*for all designated States except US*): PHARMACIA & UPJOHN S.P.A. [IT/TT]; Via Robert Koch, 1.2, I-20152 Milan (IT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GERONI, Maria, Cristina, Rosa [IT/TT]; Via Correggio, 48, I-20149 Milano (IT). COZZI, Paolo [IT/TT]; Via Zanella 48/5, I-20133 Milano (IT). BERIA, Italo [IT/TT]; Via S. Anna, 16, I-20014 Nerviano (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report
- entirely in electronic form (except for this front page) and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ALKYLATING AGENTS

(57) Abstract: The present invention provides the combined use of acryloyl distamycin derivatives, in particular α -bromo- and α -chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and an alkylating agent, in the treatment of tumors. Also provided is the use of the said combination in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis.

WO 01/97790 A2

COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ALKYLATING AGENTS

The present invention relates to the field of cancer treatment and provides an antitumor
5 composition comprising a substituted acryloyl distamycin derivative, more particularly
an α -bromo- or α -chloro-acryloyl distamycin derivative, and an alkylating agent,
having a synergistic antineoplastic effect.


Distamycin A and analogues thereof, hereinafter referred to as distamycin and
10 distamycin-like derivatives, are known in the art as cytotoxic agents useful in antitumor
therapy.

Distamycin A is an antibiotic substance with antiviral and antiprotozoal activity, having a
polypyrrole framework [*Nature* 203: 1064 (1964); *J. Med. Chem.* 32: 774-778 (1989)].

The international patent applications WO 90/11277, WO 98/04524, WO 98/21202, WO
15 99/50265, WO 99/50266 and WO 01/40181 (claiming priority from British patent
application No. 9928703.9), all in the name of the applicant itself and herewith
incorporated by reference, disclose acryloyl distamycin derivatives wherein the amidino
moiety of distamycin is optionally replaced by nitrogen-containing ending groups such
as, for instance, cyanamidino, N-methylamidino, guanidino, carbamoyl, amidoxime,
20 cyano and the like, and/or wherein the polypyrrole framework of distamycin, or part of it,
is replaced by varying carbocyclic or heterocyclic moieties.

The present invention provides, in a first aspect, a pharmaceutical composition for use
in antineoplastic therapy in mammals, including humans, comprising a
25 pharmaceutically acceptable carrier or excipient;

- an acryloyl distamycin derivative of formula (I):



wherein:

R₁ is a bromine or chlorine atom;

- R_2 is a distamycin or distamycin-like framework; or a pharmaceutically acceptable salt thereof; and
- an alkylating agent.

- 5 The present invention includes, within its scope, the pharmaceutical compositions comprising any of the possible isomers covered by the compounds of formula (I), both considered separately or in admixture, as well as the metabolites and the pharmaceutically acceptable bio-precursors (otherwise known as pro-drugs) of the compounds of formula (I).
- 10 In the present description, unless otherwise specified, with the term distamycin or distamycin-like framework R_2 we intend any moiety structurally closely related to distamycin itself, for instance by optionally replacing the ending amidino moiety of distamycin and/or its polypyrrole framework, or part of it.

- 15 Alkylating agents are widely known in the art as described in various scientific publications.

Representatives for this class of compounds are, for instance, mustards such as melphalan, chlorambucil, mechlorethamine, cyclophosphamide, ifosfamide and busulfan; nitrosoureas such as carmustine, lomustine, semustine and fotemustine; tetrazines such as dacarbazine and temozolomide; aziridines such as thiotepa and mitomycin C and

20 platinum derivatives such as cisplatin, carboplatin, oxaliplatin, nedaplatin and lobaplatin and the like.


See, for a general reference, Cancer Principles and Practice of Oncology, Lippincott-Raven Ed. (1997), 405-432.

25

According to a preferred embodiment of the invention, herewith provided are the above pharmaceutical compositions wherein the alkylating agent is selected from mustards and platinum derivatives such as cisplatin, carboplatin and oxaliplatin.

- 30 According to another preferred embodiment of the invention, herewith provided are the above pharmaceutical compositions wherein, within the acryloyl distamycin derivative

of formula (I), R_1 has the above reported meanings and R_2 is a group of formula (II) below:



wherein


5 m is an integer from 0 to 2;

n is an integer from 2 to 5;

r is 0 or 1;


X and Y are, the same or different and independently for each heterocyclic ring, a nitrogen atom or a CH group;

10 G is phenylene, a 5 or 6 membered saturated or unsaturated heterocyclic ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of formula (III) below:



wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR_3 wherein R_3 is hydrogen or C_1 - C_4 alkyl;

15 B is selected from the group consisting of




wherein R_4 is cyano, amino, hydroxy or C_1 - C_4 alkoxy; R_5 , R_6 and R_7 , the same or different, are hydrogen or C_1 - C_4 alkyl.

In the present description, unless otherwise specified, with the term C_1 - C_4 alkyl or

alkoxy group we intend a straight or branched group selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.

- 5 Even more preferred are the pharmaceutical compositions of the invention comprising the above acryloyl distamycin derivative of formula (I) wherein R_1 is bromine or chlorine; R_2 is the above group of formula (II) wherein r is 0, m is 0 or 1, n is 4 and B has the above reported meanings.

- Still more preferred, within this class, are the pharmaceutical compositions comprising
10 the compounds of formula (I) wherein R_1 is bromine or chlorine; R_2 is the above group of formula (II) wherein r is 0, m is 0 or 1, n is 4, X and Y are both CH groups and B is selected from:



- wherein R_4 is cyano or hydroxy and R_5 , R_6 and R_7 , the same or different, are hydrogen
15 or C_1 - C_4 alkyl.

- Pharmaceutically acceptable salts of the compounds of formula (I) are those with pharmaceutically acceptable inorganic or organic acids such as, for instance, hydrochloric, hydrobromic, sulfuric, nitric, acetic, propionic, succinic, malonic, citric,
20 tartaric, methanesulfonic, p-toluenesulfonic acid and the like.

Examples of preferred acryloyl distamycin derivatives of formula (I), within the compositions object of the invention, optionally in the form of pharmaceutically acceptable salts, preferably with hydrochloric acid, are:

- 25 1. N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;

2. N-(5-{{{(5-{{{(5-{{{(2-[[amino(imino)methyl]amino}propyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
- 5 3. N-(5-{{{(5-{{{(5-{{{(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
4. N-(5-{{{(5-{{{(5-{{{(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-imidazole-2-carboxamide hydrochloride;
- 10 5. N-(5-{{{(5-{{{(5-{{{(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrazole-5-carboxamide hydrochloride;
- 15 6. N-(5-{{{(5-{{{(5-{{{(3-amino-3-oxopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrazole-5-carboxamide;
- 20 7. N-(5-{{{(5-{{{(5-{{{(2-[[amino(imino)methyl]amino]ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-chloroacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
8. N-(5-{{{(5-{{{(3-[[amino(imino)methyl]amino]propyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
- 25 9. N-(5-{{{(5-{{{(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride; and
- 30 10. N-{5-[(5-[(5-[(3-[(aminocarbonyl)amino]propyl)amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl}-1-

methyl-1H-pyrrol-3-yl}-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

The above compounds of formula (I), either specifically identified as such or by means
5 of the general formula, are known or easily prepared according to known methods as reported, for instance, in the aforementioned international patent applications WO 90/11277, WO 98/04524, WO 98/21202, WO 99/50265 and WO 99/50266 as well as in WO 01/40181.

10 The present invention further provides a product comprising an acryloyl distamycin derivative of formula (I), as defined above, and an alkylating agent, as a combined preparation for simultaneous, separate or sequential use in antitumor therapy.

A further aspect of the present invention is to provide a method of treating a mammal,
15 including humans, suffering from a neoplastic disease state, which method comprises administering to said mammal the above acryloyl distamycin derivative of formula (I) and an alkylating agent, in amounts effective to produce a synergistic antineoplastic effect.

20 The present invention also provides a method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent in a mammal in need thereof, including humans, the method comprising administering to said mammal a combined preparation comprising an alkylating agent and an acryloyl distamycin derivative of formula (I), as defined above, in amounts effective to produce a synergistic
25 antineoplastic effect.

By the term "synergistic antineoplastic effect", as used herein, it is meant the inhibition of the growth tumor, preferably the complete regression of the tumor, by administering an effective amount of the combination comprising an acryloyl distamycin derivative
30 of formula (I) and an alkylating agent to mammals, including humans.

By the term “administered “ or “administering”, as used herein, it is meant parenteral and/or oral administration; the term “parenteral” means intravenous, subcutaneous and intramuscular administration.

- 5 In the method of the present invention, the acryloyl distamycin derivative may be administered simultaneously with the alkylating agent or, alternatively, both compounds may be administered sequentially in either order.

In this respect, it will be appreciated that the actual preferred method and order of administration will vary according to, inter alia, the particular formulation of the acryloyl distamycin of formula (I) being used, the particular formulation of the
10 alkylating agent being used, the particular tumor model being treated as well as the particular host being treated.

To administer the acryloyl distamycin derivative of formula (I), according to the method of the invention, the course of therapy generally employed comprises doses
15 varying from about 0.05 to about 100 mg/m² of body surface area and, more preferably, from about 0.1 to about 50 mg/m² of body surface area.

For the administration of the alkylating agent, according to the method of the invention, the course of therapy generally employed comprises:

- 20 for the administration of mustard compounds doses varying from about 1 mg/m² to about 5000 mg/m² of body surface area and, more preferably, from about 10 to about 1000 mg/m² of body surface area.

for the administration of nitrosourea derivatives doses varying from about 1 mg/m² to about 1000 mg/m² of body surface area and, more preferably, from about 10 to about
25 1000 mg/m² of body surface area.

for the administration of tetrazine and aziridine compounds doses varying from about 1 mg/m² to about 1000 mg/m² of body surface area and, more preferably, from about 10 to about 1000 mg/m² of body surface area.

for the administration of platinum derivatives doses varying from about 1 mg/m² to
30 about 1000 mg/m² of body surface area and, more preferably, from about 10 to about 500 mg/m² of body surface area.

The antineoplastic therapy of the present invention is particularly suitable for treating breast, ovary, lung, colon, kidney, stomach, pancreas, liver, melanoma, leukemia and brain tumors in mammals, including humans.

- 5 In a further aspect, the present invention is directed to the preparation of a pharmaceutical composition comprising an effective amount of an acryloyl distamycin derivative of formula (I), as defined above, and an alkylating agent, in the preparation of a medicament for use in the prevention or treatment of metastasis or in the treatment of tumors by inhibition of angiogenesis.

10

As stated above, the effect of an acryloyl distamycin derivative of formula (I) and an alkylating agent, for instance cisplatin and carboplatin, is significantly increased without a parallel increase of toxicity. In other words, the combined therapy of the present invention enhances the antitumoral effects of the acryloyl distamycin derivative and of the alkylating agent and, hence, provides the most effective and least toxic treatment for tumors.

15

The synergistic or superadditive effect of the combined preparations of the invention is shown, for instance, by the following *in vivo* tests which are intended to illustrate the present invention without posing any limitation to it.

20

Table 1 shows the antileukemic activity on disseminated L1210 murine leukemia obtained by combining the representative compound of formula (I) of the invention N-(5-{{(5-{{(5-{{(2-{{[amino(imino)methyl]amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride - internal code PNU 166196, with cisplatin.

25

At the dose of 5.9 mg/kg of cisplatin alone (day +3) and at the dose of 0.26 mg/kg of PNU 166196 alone (days +1,2) were associated, without toxicity, with ILS% values of 67 and 33, respectively.

30

Combining cisplatin and PNU 166196 at the same doses with the same schedule, an increase of activity with ILS% values of 125 were observed, thus indicating a synergistic antitumor effect.

5 **Table 2** shows the antileukemic activity on disseminated L1210 murine leukemia obtained by combining the above PNU 166196 derivative with carboplatin.

At the dose of 135 mg/kg of carboplatin alone (day +3) and at the dose of 0.26 mg/kg of PNU 166196 alone (days +1,2) were associated, without toxicity, with ILS% values of 50 and 33, respectively.

10 By combining carboplatin and PNU 166196 at the same doses and with the same schedule, an increase of activity with ILS% values of 92 were observed, again indicating a more than additive effect.

15 **Table 3** shows the antitumor effect on subcutaneous implanted HCT-116 human colon carcinoma obtained by combining PNU 166196 with cisplatin.

At the dose of 2 mg/kg of cisplatin alone (q7dx3) and at the dose of 0.4 mg/kg of PNU 166196 alone (q7dx3) were associated, without toxicity, T/C% values of 92 and 61, respectively.

20 By combining cisplatin and PNU 166196, instead, a significant increase in tumor growth delay was observed, hence indicating a therapeutic advantage of the combination (synergism) in comparison to the administration of the drugs alone.

For these experiments PNU 166196 was solubilized in water for injection, while standard pharmaceutical preparations were used for cisplatin and carboplatin.

25

Table 1: Antileukemic activity against disseminated L1210¹ murine leukemia of an acryloyl distamycin derivative (I) in combination with cisplatin.

| Compound | Treatment ² schedule | Dose (mg/kg/day) | ILS% ³ | Tox ⁴ |
|---------------------------|------------------------------------|---------------------|-------------------|------------------|
| PNU 166196 | iv +1,2 | 0.26 | 33 | 0/10 |
| Cisplatin | iv +3 | 5.9 | 67 | 0/10 |
| PNU 166196 + Cisplatin | iv +1,2 iv +3 | 0.26 + 5.9 | 120 | 0/10 |

- 1 L1210 leukemia cells (10^5 /mouse CD2F1) are injected IV on Day 0.
- 2 Treatment is given IV.
- 3 Increase in life span: [(median survival time of treated mice/median survival time of controls) x 100] -100.
- 5 4 Number of toxic deaths/number of mice.

Table 2: Antileukemic activity against disseminated L1210¹ murine leukemia of an acryloyl distamycin derivative in combination with carboplatin.

| Compound | Treatment schedule | Dose ² (mg/kg/day) | ILS% ³ | Tox ⁴ |
|--------------------------|--------------------|----------------------------------|-------------------|------------------|
| PNU 166196 | iv +1,2 | 0.26 | 33 | 0/10 |
| Carboplatin | iv +3 | 135 | 50 | 0/10 |
| PNU 166196 + Carboplatin | iv +1,2 iv +3 | 0.26 + 135 | 92 | 0/10 |

- 10 1 L1210 leukemia cells (10^5 /mouse CD2F1) are injected IV on Day 0.
- 2 Treatment is given IV.
- 3 Increase in life span: [(median survival time of treated mice/median survival time of controls) x 100] -100.
- 4 Number of toxic deaths/number of mice.

15

Table 3: Antitumor activity against human colon carcinoma HCT-116 (low/medium GST and MMR deficiency) of an acryloyl distamycin derivative in combination with cisplatin.

| Compound | Dose ^a (mg/kg) | T/C % ^b | Log cell Kill total | Tumor free/total mice ^c | WL% (day of nadir) ^d |
|------------------------|------------------------------|-------------------------------|---------------------|------------------------------------|---------------------------------|
| PNU-166196 | 0.4 | 61 | 0.15 | 0/8 | 12 (29) |
| Cisplatin | 2 | 92 | 0 | 0/7 | 12 (24) |
| PNU-166196 + Cisplatin | 0.4 + 2 | 36 (synergic) ^e | 0.7 | 1/7 | 13 (27) |


- 20 ^a Treatment IV started on day 7 after tumor implant; schedule q7dx3 of PNU 166196 administered 48 hours after cisplatin;

- ^b Tumor regression (T/C %) on day 20 after treatment (according to NCI standards:
T/C \leq 42 active);
 - ^c On day 40 after tumor implant;
 - ^d 27 days after tumor implant;
- 5 ^e Fisher's test vs. both cisplatin and PNU 166196

CLAIMS

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as active ingredient,

5 - an acryloyl distamycin derivative of formula (I):




wherein:

R₁ is a bromine or chlorine atom;

R₂ is a distamycin or distamycin-like framework; or a pharmaceutically acceptable salt thereof; and
10 - an alkylating agent.

2. A pharmaceutical composition according to claim 1 wherein the alkylating agent is selected from the group consisting of mustards such as melphalan,
15 chlorambucil, mechlorethamine, cyclophosphamide, ifosfamide and busulfan; nitrosoureas such as carmustine, lomustine, semustine and fotemustine; tetrazines such as dacarbazine and temozolomide; aziridines such as thiotepa and mitomycin C and platinum derivatives such as cisplatin, carboplatin, oxaliplatin, nedaplatin and lobaplatin.


20 3. A pharmaceutical composition according to claim 1 comprising an acryloyl distamycin derivative of formula (I)



wherein:

R₁ is a bromine or chlorine atom;

25 R₂ is a group of formula (II)



wherein


m is an integer from 0 to 2;

n is an integer from 2 to 5;

5 r is 0 or 1;

X and Y are, the same or different and independently for each heterocyclic ring, a nitrogen atom or a CH group;


G is phenylene, a 5 or 6 membered saturated or unsaturated heterocyclic ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of formula (III) below:



10

wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR₃ wherein R₃ is hydrogen or C₁-C₄ alkyl;

B is selected from the group consisting of




15 wherein R₄ is cyano, amino, hydroxy or C₁-C₄ alkoxy; R₅, R₆ and R₇, the same or different, are hydrogen or C₁-C₄ alkyl.

4. A pharmaceutical composition according to claim 3 comprising an acryloyl distamycin derivative of formula (I) wherein R₁, R₂ and B are as defined in claim 3, r is

0, m is 0 or 1 and n is 4.

5. A pharmaceutical composition according to claim 4 comprising an acryloyl distamycin derivative of formula (I) wherein R_1 and R_2 are as defined in claim 3, r is 0, m is 0 or 1, n is 4, X and Y are both CH groups and B is selected from:




wherein R_4 is cyano or hydroxy and R_5 , R_6 and R_7 , the same or different, are hydrogen or C_1 - C_4 alkyl.

6. A pharmaceutical composition according to claim 1 comprising an acryloyl distamycin derivative, optionally in the form of a pharmaceutically acceptable salt, selected from the group consisting of:
1. N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
 2. N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]amino}propyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
 3. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
 4. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-imidazole-2-carboxamide hydrochloride;

5. N-(5-{{(5-{{(5-{{(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrazole-5-carboxamide hydrochloride;
- 5 6. N-(5-{{(5-{{(5-{{(3-amino-3-oxopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrazole-5-carboxamide;
7. N-(5-{{(5-{{(5-{{(2-{{[amino(imino)methyl]amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-chloroacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
- 10 8. N-(5-{{(5-{{(3-{{[amino(imino)methyl]amino}propyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
- 15 9. N-(5-{{(5-{{(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride; and
10. N-{5-[(5-[(5-[(3-[(aminocarbonyl)amino]propyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.
- 20

7. Products comprising an acryloyl distamycin derivative of formula (I):




25 wherein:

R₁ is a bromine or chlorine atom;

R₂ is a distamycin or distamycin-like framework; or a pharmaceutically acceptable salt thereof; and an alkylating agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of tumors.

8. Products according to claim 7 wherein the alkylating agent is selected from mustards such as melphalan, chlorambucil, mechlorethamine, cyclophosphamide, ifosfamide and busulfan; nitrosoureas such as carmustine, lomustine, semustine and fotemustine; tetrazines such as dacarbazine and temozolomide; aziridines such as thiotepa and mitomycin C and platinum derivatives such as cisplatin, carboplatin, oxaliplatin, nedaplatin and lobaplatin.


9. Products according to claim 7 comprising an acryloyl distamycin derivative of formula (I)



wherein:

R₁ is a bromine or chlorine atom;

R₂ is a group of formula (II)



wherein

m is an integer from 0 to 2;

n is an integer from 2 to 5;

r is 0 or 1;


X and Y are, the same or different and independently for each heterocyclic ring, a nitrogen atom or a CH group;

G is phenylene, a 5 or 6 membered saturated or unsaturated heterocyclic ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of formula (III) below:



wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR₃ wherein R₃ is hydrogen or C₁-C₄ alkyl;

B is selected from the group consisting of



- 5 wherein R₄ is cyano, amino, hydroxy or C₁-C₄ alkoxy; R₅, R₆ and R₇, the same or different, are hydrogen or C₁-C₄ alkyl.

10. Products according to claim 7 wherein the acryloyl distamycin derivative is selected from the group as defined in claim 6.

10

11. Use of an acryloyl distamycin derivative of formula (I), as defined in any one of claims from 1 to 6, in the preparation of a medicament for use in combination therapy with an alkylating agent in the treatment of tumors.

- 15 12. Use according to claim 11 wherein the medicament further comprises the said alkylating agent.

13. Use according to claim 11 or 12 wherein the alkylating agent is as defined in claim 2.

20

14. Use according to claim 11 or 12 wherein the acryloyl distamycin derivative is selected from the group as defined in claim 6.

15. Use according to any one of claims from 11 to 14 wherein the tumor is selected from breast, ovary, lung, colon, kidney, stomach, pancreas, liver, melanoma, leukemia and brain tumors.
- 5 16. Use of an acryloyl distamycin derivative of formula (I), as defined in any one of claims from 1 to 6, in the preparation of a medicament for use in combination therapy with an alkylating agent in the prevention or treatment of metastasis or in the treatment of tumors by inhibition of angiogenesis.
- 10 17. Use according to claim 16 wherein the medicament further comprises the said alkylating agent.
18. A method of treating a mammal, including humans, suffering from a neoplastic disease state, which method comprises administering to said mammal the acryloyl
15 distamycin derivative of formula (I), as defined in any one of claims from 1 to 6, and an alkylating agent, in amounts effective to produce a synergistic antineoplastic effect.
19. A method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent, in a mammal in need thereof including humans, the method
20 comprising administering to said mammal a combined preparation comprising an alkylating agent and an acryloyl distamycin derivative of formula (I), as defined in any one of claims from 1 to 6, in amounts effective to produce a synergistic antineoplastic effect.
- 25 20. A pharmaceutical composition according to claim 1 wherein the acryloyl distamycin derivative, optionally in the form of a pharmaceutically acceptable salt, is N-(5-{{(5-{{(5-{{(2-{{amino(imino)methyl}amino}ethyl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide, and
30 the alkylating agent is a platinum derivative selected from the group consisting of cisplatin, carboplatin, oxaliplatin, nedaplatin and lobaplatin